Registration/Welcome Coffee


Introduction from the Organizing Committee

JUNE 2018 

Boston Paris Biotechnology Summit


Central Theme:

From the Promise of Raising Capital

to the Reality of Clinical Trials



Soheila Gharakhanian, Boston

Frederick E. Pierce II, FEP Capital Advisors, Cambridge

Shahin Gharakhanian, Boston 

Summit Mission and Team


Opening Address

Excellence in Biotechnology


French Official Representative
MA Official Representative
9:45 Opening Keynotes 2018 Science & Business Strategy

Leaders’ Vision, etc




David MEEK, CEO Ipsen, Paris FR & Cambridge MA.

Trans-Atlantic Synergy, My Vision & our Practice @ Ipsen


Robert G. Urban, Ph.D., Global Head, Johnson & Johnson Innovation, Boston MA.

Named as Top 100 Most Visionary Leaders in Biotechnology.

Formerly @ MIT, the founding Executive Director of the Koch Institute for Integrative Cancer Research Koch Institute.

17 Start-Ups, 50 out-licensing transactions.

Healthcare innovations, trends, challenges and aspirations


Mark Murcko, Ph.D., Drug Hunter, Pharmaceutical Executive, Mentor, Disruptive Technology Advocate. Sr. Lecturer, MIT & CSO, Relay Therapeutics, Cambridge MA.

Mark has directly contributed to seven marketed drugs and several others currently in mid-stage clinical trials.

How I hunt drugs in Boston?


US Roadmap I

Partnerships with Boston Clinical Investigators and Academic Opinion Leaders for Product Clinical Development

Is there a “Boston” model in product development?

Role of academic thought leaders in Biotech

Relations with Clinical Trial Investigators

Biotech-Academic Collaboration


Session Chair & Opening Remarks

Professor Kenneth Kaitin, Ph.D.Director TCSDD: TUFTS Center for Study of Drug Development, Boston MA. 

Camilla “Cami” Graham, MDBIDC Medical Center, Harvard Medical School & TREK Therapeutics, Boston/Cambridge MA.
Joseph F Merola, MD, MMSc, Director of Clinical Trials and Center for Skin and Related Musculoskeletal Diseases, BW Hospital, Harvard Medical School, Boston MA. 
Robert G Urban, Ph.D., Global Head, Johnson & Johnson Innovation, Boston MA.
Panel Discussion with Audience
12:10 Working Lunch

Official Representatives

Soheila Gharakhanian: Extended Acknowledgement of SPONSORS & Introducing Exhibit

Entrepreneur’s Special Testimonial

Sebastien Christian, CEO OtoSense, Cambridge MA & Palo Alto CA.

“From a French Idea to an American Success:

How Boston has been the perfect environment to establish and grow my Company”

Lunch & Networking
Sponsors Exhibit
1:45 pm

US Roadmap II

What is Your Regulatory Strategy?

The need for Strategic Regulatory Operations

FDA Update Circa 2018

Pragmatic FDA / EMA comparisons

Panel Moderator: Emmanuelle Trombe, Partner McDermott Will & Emery, Paris, FR.

Mark De Rosch, Ph.D.

Senior VP, Regulatory Affairs and Quality Assurance at Nightstar Therapeutics, Lexington, MA.

Veleka R Peeples-Dyer, Partner

Co-Leader, FDA Practice, Life Sciences Industry Group, McDermott, Will & Emery, Washington, DC.

Panel discussion with audience
Break incorporated: beverages & snacks
available in the adjacent lounge area
 2:45 pm

Global Roadmap III

Part 1

US Entry & Funding Forum

Selected Companies Pitch to a Boston Panel of Executives, Experts & Investors.

Aspect Biosystems



Pathmaker Neurosciences

Trek Therapeutics


Short introductory presentations from the Panel

Each CEO will pitch

Feedback from the Panel will follow including “tips” & recommendations

Interaction with the audience

Session Chair & Opening Remarks

Pravin R. Chaturvedi, Ph.D.Chairman of the Scientific Advisory Board, Napo Pharmaceuticals, CEO $ Co-Founder, Oceanyx Pharmaceuticals, Woburn MA.

Nicola La Monica, Ph.D., Senior Director, Infectious Disease Scientific Innovation @ Janssen, Pharmaceutical Companies of Johnson & Johnson.

Cynthia “Cindy” LANDER, Ph.D., Partner, Nascent Enterprises, venture catalyst partnership, CEO Moerae Matrix, Greater New York Area, NY
Michel Nowak, Managing Partner, Nowak Ventures LLC, Boston.
Kevin J. Scanlon, Ph.D., Investment Advisor, Sky Venture Group, Professor of Practice, School of Business, Northeastern University, Boston MA.

Patrick Tricoli, PharmD, MBA, CEO Nanobiotix Corp, Nanobiotix US affiliate.

Jean-Marie Vallet, Representing Launchpad Venture Group. An Angel Investor providing business services to small life sciences companies through his consulting practice, Cyrma Ventures LLC
Short Coffee Break
4:00 pm

Global Roadmap III

Part 2

EU Market Entry Forum


Panel Moderator

Julius Steffen, Manager, Bionest Partners, New York.

Rogerio Vivaldi, MD, MBA, Executive Vice President, Chief Global Therapeutic Operations Officer, Bioverativ, Waltham, MA.

Francis Marsland, General Counsel and Head of Business Development, Vicarius Pharma, Switzerland.

Sandford D. Smith, Managing Director, Tullis Health Investors & Past EVP of Genzyme Corporation & President, of its International Group, South San Francisco, CA.

 4:45 pm  SUMMIT Adjourns